Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.
Its lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine.

Type
Public
HQ
Bothell, US
Founded
2004
Size (employees)
176 (est)
Alder BioPharmaceuticals was founded in 2004 and is headquartered in Bothell, US
Report incorrect company information

Key People/Management at Alder BioPharmaceuticals

John Latham

John Latham

Chief Scientific Officer
Larry Benedict

Larry Benedict

Vice President, Finance
Mark Litton

Mark Litton

Chief Business Officer and Treasurer
Paul Cleveland

Paul Cleveland

Interim President and Chief Executive Officer

Alder BioPharmaceuticals Office Locations

Alder BioPharmaceuticals has an office in Bothell
Bothell, US (HQ)
11804 North Creek Parkway
Show all (1)
Report incorrect company information

Alder BioPharmaceuticals Financials and Metrics

Alder BioPharmaceuticals Financials

USD

Net income (Q1, 2018)

(87 m)

EBIT (Q1, 2018)

(85.7 m)

Market capitalization (15-Jun-2018)

1.2 b

Closing share price (15-Jun-2018)

17.7

Cash (31-Mar-2018)

202 m
Alder BioPharmaceuticals's current market capitalization is $1.2 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cost of goods sold

113 k1.6 m

General and administrative expense

12.5 m16.7 m26.1 m38.1 m

R&D expense

33.4 m69.6 m132.8 m252.9 m

Operating expense total

45.9 m86.3 m158.9 m292.6 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cost of goods sold

113 k113 k683 k

General and administrative expense

3.2 m2.7 m3.2 m3.7 m3.9 m4.3 m6 m6.5 m6.2 m10 m9.5 m11.7 m

R&D expense

7 m9.4 m7 m11 m14.1 m22.9 m27.6 m33.8 m29.5 m90.7 m65.3 m74 m

Operating expense total

10.2 m12.1 m10.2 m14.7 m18 m27.2 m33.7 m40.4 m35.7 m100.7 m75.5 m85.7 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

46.8 m206.5 m116.2 m76.9 m

Accounts Receivable

113 k113 k

Inventories

28.2 m936 k

Current Assets

60.7 m322.2 m393.2 m287.3 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

12.9 m70.3 m57.6 m209.9 m408 m234 m178 m230 m170.6 m79.7 m127.8 m202 m

Accounts Receivable

91 k57 k81 k113 k113 k113 k

Inventories

936 k936 k936 k936 k

Current Assets

14.3 m81.8 m73.8 m241.6 m442.1 m319.8 m319.7 m464.1 m428 m310.3 m246.6 m340.7 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

8.9 m(85.5 m)(156.3 m)(288.9 m)

Depreciation and Amortization

701 k751 k1.7 m3 m

Inventories

95 k(936 k)936 k

Accounts Payable

(312 k)2.8 m5.5 m(2.4 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(5.4 m)(7.4 m)28.6 m(14.7 m)(17.7 m)(27 m)(33.4 m)(38.9 m)(35.1 m)(100.3 m)(87 m)

Depreciation and Amortization

801 k

Inventories

936 k936 k936 k

Accounts Payable

2.8 m1.8 m2.2 m2.4 m7.7 m9.6 m8.4 m5.7 m20.3 m5.3 m
USDY, 2018

Financial Leverage

2 x
Show all financial metrics
Report incorrect company information

Alder BioPharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information